DiaSorin

Company Presentation
March 2022
 About us

WORLD LEADERS IN THE LAB DIAGNOSTICS MARKET, WE ARE SPECIALISTS

IN THE IMMUNODIAGNOSTIC AND MOLECULAR DIAGNOSTIC SEGMENTS
AND ACTIVE IN THE LICENSED TECHNOLOGY BUSINESS

We have been developing, producing and marketing reagent kits for laboratory
diagnostics all over the world, for over 50 years. Our broad offering of diagnostic tests
and Licensed Technology solutions, made available thanks to ongoing investments in
research, positions us as the player with the widest range of specialty solutions in the
sector and identifies the Group as the "Diagnostics Specialist". Listed on the Italian
Stock Exchange
Diagnosis is the first step towards understanding a person’s state of health. This is in the FTSE MIB
Index
why our tests can make the difference: they are precise and reliable and enable
delivery of early diagnosis of various pathologies for millions of people who will then
be able to receive the most appropriate therapy.
 Our business

IN VITRO DIAGNOSTICS LICENSED TECHNOLOGIES

We market and develop diagnostic tests and solutions
in the immunodiagnostic and molecular diagnostic sectors
We offer technological and innovative solutions ranging
from hospital and commercial analysis laboratories
to decentralized contexts
We help scientists get quick and reliable responses
to complex biological issues with an innovative
and unique technology supporting different markets
including biomedical research, genomic and proteomic
research, clinical diagnostics and drug development

1. LABORATORY DIAGNOSTICS
The doctor prescribes
DIAGNOSTIC TESTS
The outcome of the tests performed by the patient will allow the doctor to take the most correct therapeutic path
2. POINT OF CARE DIAGNOSTICS
A patient goes into a PHARMACY
to monitor a parameter or identify a
pathology
3. LICENSED TECHNOLGIES
Healthcare sector clients need to
DEVELOP A NEW PRODUCT
(drug, test, vaccine, etc.)
From needs to our solutions
In the laboratory, the samples are processed
The patient has The samples are univocally
by SPECIALIZED EQUIPMENT that provides
SAMPLES taken in a classified, labelled and
the diagnostic responses required on the basis
healthcare facility or ANALYZED IN A
of the reaction between the samples and the
analysis laboratory LABORATORY
DIAGNOSTIC TEST REAGENTS
A healthcare operator TAKES THE PLATFORM DELIVERS
A SAMPLE AND THE RESULT to the patient in
PROCESSES THE TEST digital or paper format very quickly
DiaSorin provides the The client initiates the FINISHED
PLATFORM FOR DEVELOPEMENT AND
PRODUCT
RESEARCH AND THE RESEARCH PROCESS
LAUNCH
TECHNOLOGY
 Our History
DiaSorin launches the LIAISON IQ
analyzer with Lumos Diagnostics for
Point-of-Care (POC)
immunodiagnostics

DiaSorin continues to grow DiaSorin acquires the US company

Foundation of SORIN, a
nuclear energy production
center in Saluggia (Vercelli,
Italy), by a JV between FIAT
and Montecatini
The opening of Europe’s first
in vitro diagnostics center
A management
buyout brings DiaSorin
ownership back to Italy
organically and inorganically,
expanding geographically
and investing in technology and
product innovation.
It forms numerous
partnerships with leading players
in the global diagnostics market
(Roche, Beckman Coulter, Meridian
Bioscience)
DiaSorin stock is included in the
FTSE MIB
DiaSorin enters a partnership
with Qiagen for latent
tuberculosis testing
DiaSorin acquires Siemens
Healthineers’ ELISA business
Luminex Corporation for $1.8bn,
thus gaining multiplexing technology
for molecular diagnostics and
entering in the Licensed
Technology field
DiaSorin launches the Lyme
test in partnership with QIAGEN and
the MeMed BV test in partnership
with MeMed

1968 2000 2010-2015 2018 2021

1997 2007 2016 2020

DiaSorin, the diagnostics division
of SORIN Group, is sold to the
multinational American
Standard International
On July 19, DiaSorin is
listed on the Italian
stock exchange
(Piazza Affari, Milan)
DiaSorin enters the molecular
diagnostic sector by
acquiring the American Focus
Diagnostics, now DiaSorin
Molecular, adding to the
Group’s competence and
excellence
DiaSorin signs an exclusive
license agreement with
TTP for the development of a
molecular Point-of-Care
(POC) solution
Launch of 5 COVID tests
 DiaSorin worldwide

EUROPE
NORTH AMERICA & AFRICA
44% of Group Revenues 39%
of Group
USA | Austin - Chicago - Cypress
Revenues
Madison - Seattle - Stillwater ITALY | Saluggia - Gerenzano
CHINA| Shanghai FROM 2023
CANADA | Toronto GERMANY | Dietzenbach
UK | Dartford

~3,300
Employees

REST OF THE WORLD

17% of Group Revenues
R&D and Operations

Data as of December 31, 2021 R&D

Direct Presence
Countries served
Operations through distributors
 Financials

Data in € mln

1238

881

706
669
637
569
543
499
440 434 435 444
404 385

304
277
245 238 255
202 217
190 185
167 170 163 160
124
60 86

2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021
Revenues Adjusted EBITDA
 Our business by tech

8%
Licensed Technologies

57%
Immunodiagnostics
35%
Molecular Diagnostic

Data as of December 31, 2021

 M&A & Partnerships

Molecular Immunodiagnostics
Point-of-Care Point-of-Care
(POC) Platform (POC) Platform

PARTNERSHIPS Hepatitis QuantiFERON

GI Stool Test Connectivity for
& Retrovirus Technology
lab automation

Bacterial vs. Viral infection testing

2000-2009 2010 - 2014 2015 - 2019 2020 - Today

Byk Sangtec ( ) ( )
CLIA Parvovirus ELISA Hepatitis Molecular Molecular ELISA Business Multiplexing &
M&A & Retrovirus Diagnostics Diagnostics Licensed Technologies
immunodiagnostic
platform
 Our Immunodiagnostic Systems

LIAISON® IQ LIAISON® XS LIAISON® XL/ XL LAS LIAISON® XXL*

NEAR-PATIENT SMALL-TO-MEDIUM LABS

MEDIUM-TO-LARGE LABS

CLINICAL AREAS

o Infectious diseases o Autoimmunity o Bone & mineral

o Endocrinology o Hypertension o Oncology

o Stool diagnostics

* To be launched
 Our Molecular Diagnostic Systems
LIAISON® NES* ARIES® LIAISON® MDx LIAISON® MDx Plus* Luminex® 100/200 MAGPIX® Verigene® LIAISON® Plex*

NON-AUTOMATED AUTOMATED

NEAR PATIENT SINGLE-LOW PLEX PLATFORMS MULTIPLEXING PLATFORMS

Detects the presence of up to 5 pathogen agents Simultaneously detects the presence of up to 40 different
starting from a single sample pathogens from a single sample

CLINICAL AREAS

o Respiratory Infections o Hospital Acquired Infections o Transplant

o Herpes viruses o Vector borne o Women's/Neonatal Health

o Meningitis/Encephalitis o Bloodstream Infections o Genetics/Cystic Fibrosis

* To be launched
 Our Licensed Technologies Systems

Guava® Amnis®
Luminex® 100/200 FLEXMAP 3D® MAGPIX® xMAP® INTELLIFLEX Guava® Muse® ImageStream®X Mk II Amnis FlowSight®
easyCyteTM / HT CellStream®

LICENSED TECHNOLOGIES GROUP FLOW CYTOMETRY

MAIN APPLICATIONS MAIN APPLICATIONS

o Allergy Testing o Endocrine o Neurobiology/Brain and o Cell Health o Advanced Phenotyping
o Alzheimer o Gene Expression Profiling Nervous System Markers o Cell Pathways & Analysis
o Autoimmune Disease o Genotyping o Plant & Food Safety o Autophagy o Cell Function &
o Biodefense/Environmental o HLA Testing o Sepsis Markers o Immunology Mechanism
o Cancer Markers o Immunogenicity o Transcription Factors/Nuclear o Malaria Research o Statistical microscopy
o Cardiac Markers o Infectious Disease Receptors o Cell Absolute Counting applications
o Cellular Signaling o Isotyping o Toxicology o Small Particle detection
o Cytokines, Chemokines and o Matrix Metalloproteinase o Vaccine Testing o Immunological
Growth Factors o Metabolic Markers Phenotyping